Saturday 10 October 2026 Export all BMY data to Excel Powerpack

Bristol Myers Squibb Company

BMY Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

59.12 0.46 −0.77%
Market cap
$121.7B
P/E
13.0×
Fwd P/E
11.2×
Dividend yield
4.26%
F-score
8/9
Altman Z
2.14
Beneish M
−2.69
Dividend safety
63/100

Bristol Myers Squibb Company (BMY) EV/FCF

Alert me on EV/FCF

As of 9 October 2026, Bristol Myers Squibb Company (BMY) trades at a EV/FCF of 13.4×. Over the past ten years it has ranged from 7.8× (October 2025) to 389× (June 2016); the current reading is higher than 45% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 11.2× 1.97%
FY2024 11.0× 1.89%
FY2023 10.8× (29.85%)
FY2022 15.4× 41.26%
FY2021 10.9× (17.12%)
FY2020 13.2× (31.11%)
FY2019 19.1× 39.86%
FY2018 13.7× (43.53%)
FY2017 24.2× (55.32%)
FY2016 54.1× (40.63%)

Quarterly newest first

Period EV/FCF Change
Jun 2026 13.1× (1.10%)
Mar 2026 13.2× 17.92%
Dec 2025 11.2× 38.15%
Sep 2025 8.1× (8.76%)
42 more quarters

Against its own ten years

Low 7.8× High 389×
Ten-year median 14.0×
Current reading's percentile 49

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on BMY